CORRECTION article

Front. Public Health, 13 November 2024

Sec. Children and Health

Volume 12 - 2024 | https://doi.org/10.3389/fpubh.2024.1517339

Corrigendum: The concentration of maternal sacubitril/valsartan transferred into human milk is negligible

  • 1. School of Medicine, Texas Tech University Health Sciences Center, Amarillo, TX, United States

  • 2. Department of Obstetrics and Gynecology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, United States

  • 3. Department of Cardiology, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States

  • 4. Department of Obstetrics and Gynecology, School of Medicine, Texas Tech University Health Sciences Center, Amarillo, TX, United States

In the published article, there was an error. The currently published article does not acknowledge a previously published study. We would like to add the missing data and properly reference the earlier work.

A correction has been made to Discussion, paragraph one.

This sentence previously stated:

“There are no previous studies evaluating the transfer of any NEP inhibitor (e.g., sacubitril) or ARB (e.g., valsartan) into human milk, limiting the use of these drug classes in breastfeeding mothers suffering from HF.”

The corrected sentence appears below:

“There are no previous studies evaluating the transfer of any NEP inhibitor (e.g., sacubitril) into human milk. A single case series has reported the limited transfer of one ARB, candesartan, into human milk (). This scarcity of data restricts the use of these drug classes in breastfeeding mothers suffering from HF.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Summary

Keywords

heart failure, entresto, lactation, pharmacology, peripartum cardiomyopathy (PPCM), maternal health

Citation

Falconi S, Okimi A, Wesley S, Sethi P, Datta P and Krutsch K (2024) Corrigendum: The concentration of maternal sacubitril/valsartan transferred into human milk is negligible. Front. Public Health 12:1517339. doi: 10.3389/fpubh.2024.1517339

Received

25 October 2024

Accepted

31 October 2024

Published

13 November 2024

Volume

12 - 2024

Edited and reviewed by

Charlotte Cosemans, University of Hasselt, Belgium

Updates

Copyright

*Correspondence: Kaytlin Krutsch

†These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics